MX2018014911A - Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas. - Google Patents
Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas.Info
- Publication number
- MX2018014911A MX2018014911A MX2018014911A MX2018014911A MX2018014911A MX 2018014911 A MX2018014911 A MX 2018014911A MX 2018014911 A MX2018014911 A MX 2018014911A MX 2018014911 A MX2018014911 A MX 2018014911A MX 2018014911 A MX2018014911 A MX 2018014911A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- therapy
- cell
- treating
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 title abstract 2
- 230000036210 malignancy Effects 0.000 title abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan métodos de terapia de célula adoptiva que implica la administración de dosis de células para tratar afecciones malignas de células B. Las células que expresan en general receptores recombinantes tal como receptores de antígeno quiméricos (CARs). En algunas modalidades, los métodos son para tratar sujetos con leucemia linfocítica crónica (CLL). En algunas modalidades, los métodos son para tratar sujetos con linfoma no de Hodgkin (NHL). En algunas modalidades, los métodos implican la administración previa de una terapia reductora de linfocitos, tal como administración previa de fludarabina y/u otro agente quimioterapéutico reductor de linfocitos, por ejemplo ciclofosfamida. En algunas modalidades, las características de los métodos incluyen un incremento en la remisión completa, supervivencia total y/o supervivencia sin progresión de sujetos tratados de acuerdo con los métodos proporcionados.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346547P | 2016-06-06 | 2016-06-06 | |
US201662417292P | 2016-11-03 | 2016-11-03 | |
US201662429737P | 2016-12-03 | 2016-12-03 | |
PCT/US2017/036231 WO2017214207A2 (en) | 2016-06-06 | 2017-06-06 | Methods for the treatment of b cell malignancies using adoptive cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014911A true MX2018014911A (es) | 2019-08-12 |
Family
ID=59227902
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014911A MX2018014911A (es) | 2016-06-06 | 2017-06-06 | Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas. |
MX2024000151A MX2024000151A (es) | 2016-06-06 | 2018-11-30 | Composiciones y usos de las mismas para el tratamiento de afecciones malignas de celulas t usando terapias de celulas adoptivas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2024000151A MX2024000151A (es) | 2016-06-06 | 2018-11-30 | Composiciones y usos de las mismas para el tratamiento de afecciones malignas de celulas t usando terapias de celulas adoptivas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200016199A1 (es) |
EP (1) | EP3463437A2 (es) |
JP (3) | JP7139318B2 (es) |
KR (3) | KR20240036704A (es) |
CN (1) | CN109562151A (es) |
AU (1) | AU2017277396B2 (es) |
BR (1) | BR112018074406A2 (es) |
CA (1) | CA3024725A1 (es) |
MA (1) | MA45341A (es) |
MX (2) | MX2018014911A (es) |
WO (1) | WO2017214207A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106610A (zh) | 2014-10-20 | 2017-08-29 | 朱诺治疗学股份有限公司 | 用于过继细胞治疗中的给药的组合物和方法 |
EP3245231B1 (en) | 2015-01-16 | 2020-08-12 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
ES2903228T3 (es) | 2016-02-02 | 2022-03-31 | Hutchinson Fred Cancer Res | Anticuerpos anti-ROR1 y usos de los mismos |
CN110139669A (zh) * | 2016-11-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | T细胞疗法和btk抑制剂的组合疗法 |
MX2019006288A (es) | 2016-12-03 | 2020-10-01 | Juno Therapeutics Inc | Metodos y composiciones para el uso de celulas t terapeuticas en combinacion con inhibidores de quinasa. |
JP7359751B2 (ja) | 2017-03-14 | 2023-10-11 | ジュノー セラピューティクス インコーポレイテッド | 極低温保管のための方法 |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
KR20200096758A (ko) | 2017-10-18 | 2020-08-13 | 인트렉손 코포레이션 | 스페이서를 포함하는 폴리펩타이드 조성물 |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
WO2019200347A1 (en) * | 2018-04-13 | 2019-10-17 | Fred Hutchinson Cancer Research Center | Methods for adoptive cell therapy targeting ror1 |
CA3098497A1 (en) * | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
EP3873539A4 (en) * | 2018-10-31 | 2023-01-18 | The Children's Hospital of Philadelphia | T LYMPHOCYTES FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE |
PT3886875T (pt) * | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
FI3886894T3 (fi) * | 2018-11-30 | 2024-05-24 | Juno Therapeutics Inc | Menetelmiä annosteluun ja b-solumaligniteettien hoitoon adoptiivisessa soluterapiassa |
KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
AU2020307667A1 (en) * | 2019-06-27 | 2022-01-20 | Crispr Therapeutics Ag | Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer |
BR112022010310A2 (pt) * | 2019-12-06 | 2022-08-16 | Juno Therapeutics Inc | Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b |
US20230071910A1 (en) * | 2020-01-24 | 2023-03-09 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
CN115768443A (zh) * | 2020-02-12 | 2023-03-07 | 朱诺治疗学股份有限公司 | Cd19定向嵌合抗原受体t细胞组合物和方法及其用途 |
EP4153616A4 (en) * | 2020-05-18 | 2024-08-21 | Robert Sackstein | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS |
EP4161563A1 (en) * | 2020-06-05 | 2023-04-12 | Tessa Therapeutics Ltd. | Treatment of cd30-positive cancer |
WO2021260657A1 (en) * | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
WO2022084862A1 (en) * | 2020-10-20 | 2022-04-28 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
RU2758126C1 (ru) * | 2021-04-02 | 2021-10-26 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ прогнозирования развития рецидива диффузной В-крупноклеточной лимфомы |
WO2022254337A1 (en) * | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
EP0452342B1 (en) | 1988-12-28 | 1994-11-30 | MILTENYI, Stefan | Methods and materials for high gradient magnetic separation of biological materials |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Cd19特異的再指向免疫細胞 |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
EP2856876B1 (en) | 2007-03-30 | 2018-01-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
JP5456689B2 (ja) | 2007-12-07 | 2014-04-02 | ミルテンイ バイオテック ゲーエムベーハー | 試料を少なくとも2つの成分に分離する遠心分離機 |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
WO2010025177A1 (en) | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
ES2748126T3 (es) * | 2008-11-07 | 2020-03-13 | Amgen Res Munich Gmbh | Tratamiento de leucemia linfoblástica aguda pediátrica con anticuerpos biespecíficos contra CD3XCD19 |
PT2496698T (pt) | 2009-11-03 | 2019-04-18 | Hope City | Recetor de fator de crescimento epidermal truncado (egfrt) para seleção de células t transduzidas |
SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
SG11201407175RA (en) | 2012-05-03 | 2014-12-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
ES2859522T3 (es) * | 2012-07-13 | 2021-10-04 | Univ Pennsylvania | Control de la toxicidad para la actividad antitumoral de CAR |
SG11201501259QA (en) | 2012-08-20 | 2015-03-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
RU2020124583A (ru) | 2012-10-02 | 2020-08-03 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
DE112012007250T5 (de) | 2012-12-20 | 2015-10-08 | Mitsubishi Electric Corp. | Fahrzeuginterne Vorrichtung und Programm |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
-
0
- MA MA045341A patent/MA45341A/fr unknown
-
2017
- 2017-06-06 EP EP17733663.3A patent/EP3463437A2/en active Pending
- 2017-06-06 US US16/307,462 patent/US20200016199A1/en active Pending
- 2017-06-06 JP JP2019516103A patent/JP7139318B2/ja active Active
- 2017-06-06 MX MX2018014911A patent/MX2018014911A/es unknown
- 2017-06-06 KR KR1020247007298A patent/KR20240036704A/ko active Search and Examination
- 2017-06-06 KR KR1020197000351A patent/KR102540751B1/ko not_active Application Discontinuation
- 2017-06-06 BR BR112018074406-9A patent/BR112018074406A2/pt unknown
- 2017-06-06 CN CN201780046873.8A patent/CN109562151A/zh active Pending
- 2017-06-06 CA CA3024725A patent/CA3024725A1/en active Pending
- 2017-06-06 KR KR1020237018556A patent/KR102644950B1/ko active IP Right Grant
- 2017-06-06 AU AU2017277396A patent/AU2017277396B2/en active Active
- 2017-06-06 WO PCT/US2017/036231 patent/WO2017214207A2/en unknown
-
2018
- 2018-11-30 MX MX2024000151A patent/MX2024000151A/es unknown
-
2021
- 2021-12-08 JP JP2021199037A patent/JP2022033929A/ja active Pending
-
2023
- 2023-11-07 JP JP2023189795A patent/JP2023184646A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2024000151A (es) | 2024-01-23 |
EP3463437A2 (en) | 2019-04-10 |
KR102644950B1 (ko) | 2024-03-11 |
WO2017214207A3 (en) | 2018-01-18 |
CN109562151A (zh) | 2019-04-02 |
KR20190026740A (ko) | 2019-03-13 |
JP2022033929A (ja) | 2022-03-02 |
CA3024725A1 (en) | 2017-12-14 |
AU2017277396A1 (en) | 2018-11-29 |
JP2019517589A (ja) | 2019-06-24 |
WO2017214207A2 (en) | 2017-12-14 |
US20200016199A1 (en) | 2020-01-16 |
KR102540751B1 (ko) | 2023-06-09 |
BR112018074406A2 (pt) | 2019-03-06 |
KR20230085947A (ko) | 2023-06-14 |
MA45341A (fr) | 2019-04-10 |
JP2023184646A (ja) | 2023-12-28 |
AU2017277396B2 (en) | 2024-08-01 |
KR20240036704A (ko) | 2024-03-20 |
WO2017214207A8 (en) | 2018-11-29 |
JP7139318B2 (ja) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024000151A (es) | Composiciones y usos de las mismas para el tratamiento de afecciones malignas de celulas t usando terapias de celulas adoptivas. | |
PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
PH12019500369A1 (en) | Anti-tim-3 antibodies | |
PH12019501227A1 (en) | Synthetic immune receptors and methods of use thereof | |
MX2021006244A (es) | Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva. | |
MX2019011858A (es) | Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos. | |
MX2021006238A (es) | Metodos para tratamiento que usan terapia celular adoptiva. | |
WO2018068008A8 (en) | T cells expressing membrane-anchored il-12 for the treatment of cancer | |
PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
WO2015110923A3 (en) | Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia | |
MX2020011527A (es) | Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa. | |
MX2021005024A (es) | Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b. | |
WO2018009528A8 (en) | Combination cancer immunotherapies with arginine depletion agents | |
MX2021015317A (es) | Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia. | |
PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
CO2021011034A2 (es) | Métodos para tratar el mieloma múltiple | |
PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
ZA202104195B (en) | Hybrid promoters and their uses in therapy, notably for treating type ii collagenopathies | |
ZA201907623B (en) | T cells with reduced surface fucosylation and methods of making and using the same | |
PH12019550033A1 (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
MX2022006715A (es) | Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b. | |
MX2023013228A (es) | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. | |
MX2021005734A (es) | Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b. | |
MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
WO2019133454A3 (en) | Methods to improve the therapeutic index of activated t cells |